{
    "clinical_study": {
        "@rank": "112435", 
        "arm_group": {
            "arm_group_label": "Double Blinded", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity\n      (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and\n      to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients.\n      Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed."
        }, 
        "brief_title": "A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men aged 30 to 90 years old with prostate adenocarcinoma who have already made their\n             treatment selection of RARP, and only men with an AUA symptom score greater than 7\n             will be included.  All subjects must be able to read and comprehend fully the\n             informed consent.\n\n        Exclusion Criteria:\n\n          -  Men with prostate neoplasms other than adenocarcinoma\n\n          -  Subjects receiving other treatments for prostate cancer will be excluded.\n\n          -  Any subject with a preexisting bladder disease will be excluded.\n\n          -  Subjects with acute urinary retention and/or deceased gastointestinal motility.\n\n          -  Subjects with glaucoma.\n\n          -  Subjects with hepatic or renal impairment.\n\n          -  Subjects taking CYP3A4 Inhibitors (e.g.ketoconazole, intraconazole, clarithromycin).\n\n          -  Subjects with myasthenia gravis\n\n          -  Subjects who are unwilling or unable to complete the subject questionnaires\n\n          -  Subjects, who in the opinion of the investigator, would be non-compliant with the\n             majority of the visits scheduled or study procedures."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "146", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661166", 
            "org_study_id": "UPCC 15810"
        }, 
        "intervention": {
            "arm_group_label": "Double Blinded", 
            "description": "4 mg", 
            "intervention_name": "Fesoterodine", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Male adult subjects", 
            "aged 30-90 years", 
            "RARP", 
            "AUA symptom score greater than 7 will be included"
        ], 
        "lastchanged_date": "February 25, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "David Lee, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "David Lee, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy )", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "David Lee, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "David Lee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}